早期肝癌无创诊断之匙——循环游离DNA联合型液体活检

叶婷丹; 雷学忠

doi:10.3969/j.issn.1001-5256.2022.04.037

早期肝癌无创诊断之匙——循环游离DNA联合型液体活检

DOI: 10.3969/j.issn.1001-5256.2022.04.037

叶婷丹¹,
雷学忠^2, , ,

1.
四川大学华西临床医学院，成都 610041
2.
四川大学华西医院感染性疾病中心，成都 610041

基金项目:

“十三五”国家科技重大专项 (2017ZX10202203-008-005)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：叶婷丹对研究的思路或设计有关键贡献，参与了研究数据的获取分析解释过程，参与起草或修改文章关键内容; 雷学忠负责指导撰写文章并最后定稿。

详细信息

通信作者:
雷学忠，18980601317@163.com

计量
- 文章访问数: 776
- HTML全文浏览量: 263
- PDF下载量: 128
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-12
- 出版日期: 2022-04-20

Circulating cell-free DNA-combined liquid biopsy: The key to noninvasive diagnosis of early-stage liver cancer

Tingdan YE¹,
Xuezhong LEI^{2
, ,
,}

1.
West China School of Medicine, Sichuan University, Chengdu 610041, China
2.
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China

Research funding:

National Major Scientific and Technological Special Project during the Thirteenth Five-year Plan Period (2017ZX10202203-008-005)

More Information

Corresponding author: LEI Xuezhong, 18980601317@163.com(ORCID: 0000-0002-2760-8839)

摘要

摘要: 循环游离DNA(cfDNA)被认为是诊断早期肝癌极具研究前景的液体活检切入点。但不少研究证实单独使用cfDNA作为检测指标其诊断效能缺乏稳定性，尤其是单纯定量分析并不能很好地反映肿瘤情况。而更多研究表示cfDNA适宜多指标联合检测或与其他肝癌诊断标志物进行联合检测。本文回顾了截至2021年7月以cfDNA为出发点的联合型液体活检相关文献，归纳了现有研究中的各联合检测方式，首次就其联合诊断方法的诞生及研究进展进行简要综述，进一步明确cfDNA联合液体活检在诊断早期肝癌中的重要意义与潜力，以期为更好地利用肝癌诊断标志物提供探索思路。
- 肝肿瘤 /
- 活组织检查 /
- 循环游离DNA /
- 诊断
Abstract: Circulating cell-free DNA (cfDNA) is considered a promising entry point of liquid biopsy for the diagnosis of early-stage liver cancer; however, many studies have confirmed that the diagnostic efficacy of cfDNA alone is not stable, especially that quantitative test alone cannot well reflect the situation of tumor. More and more studies have shown that cfDNA is suitable for combined measurement of multiple indicators or combined measurement with other diagnostic markers for liver cancer. This article reviews the articles on combined liquid biopsy based on cfDNA published up to July 2021, summarizes the existing methods for combined measurement, and briefly describes the birth and research advances in combined diagnostic methods, so as to further clarify the significance and potential of combined liquid biopsy based on cfDNA in the diagnosis of early-stage liver cancer and thus provide ideas for taking better advantages of the diagnostic markers for liver cancer in the future.
- Liver Neoplasms /
- Biopsy /
- Circulating Free DNA /
- Diagnosis

HTML全文

参考文献(46)

[1]	Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer (2021 edition)[J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008. 中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
[2]	LIU J, LIU D, GUO P. Research progress of peripheral blood cfDNA and its methodology in clinical transformation[J]. Chin J Gerontol, 2020, 40(8): 1785-1789. DOI: 10.3969/j.issn.1005- 9202.2020.08.060. 刘杰, 刘冬, 郭鹏. 外周血cfDNA及其在临床转化中的方法学研究进展[J]. 中国老年学杂志, 2020, 40(8): 1785-1789. DOI: 10.3969/j.issn.1005- 9202.2020.08.060.
[3]	LI GY, LI JY, ZHUANG KM, et al. Progress on circulating tumor DNA in early diagnosis of hepatocellular carcinoma[J/CD]. Chin J Liver Dis (Electronic Version), 2020, 12(3): 6-11. DOI: 10.3969/j.issn.1674-7380.2020.03.002. 李国印, 李金莹, 庄康敏, 等. 循环肿瘤DNA在肝细胞癌早期诊断中的研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(3): 6-11. DOI: 10.3969/j.issn.1674-7380.2020.03.002.
[4]	GAI W, SUN K. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy[J]. Genes (Basel), 2019, 10(1): 32. DOI: 10.3390/genes10010032.
[5]	HOU YJ, ZHANG LQ, FAN HN, et al. Research advances in circulating free DNA in liver cancer and liver-related parasitic diseases[J]. J Clin Hepatol, 2020, 36(2): 430-432. DOI: 10.3969/j.issn.1001-5256.2020.02.043. 后亚军, 张灵强, 樊海宁. 循环游离DNA在肝癌和肝相关性寄生虫病中的应用进展[J]. 临床肝胆病杂志, 2020, 36(2): 430-432. DOI: 10.3969/j.issn.1001-5256.2020.02.043.
[6]	ZHANG T, YIN M, WANG L, et al. Diagnostic performance of blood-based liquid biopsies in hepatocellular carcinoma: A protocol for systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(41): e22594. DOI: 10.1097/MD.0000000000022594.
[7]	YE Q, LING S, ZHENG S, et al. Liquid biopsy in hepatocellular carcinoma: Circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114. DOI: 10.1186/s12943-019-1043-x.
[8]	XU RH, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997.
[9]	CHEN VL, XU D, WICHA MS, et al. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: A systematic review[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2879-2902. e9. DOI: 10.1016/j.cgh.2020.04.019.
[10]	QIN Z, LJUBIMOV VA, ZHOU C, et al. Cell-free circulating tumor DNA in cancer[J]. Chin J Cancer, 2016, 35(5): 1-9. DOI: 10.1186/s40880-016-0092-4.
[11]	LIAO W, MAO Y, GE P, et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: A meta-analysis[J]. Medicine (Baltimore), 2015, 94(14): e722. DOI: 10.1097/MD.0000000000000722.
[12]	WANG T, ZHANG KH, HU PP, et al. Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: An integrative approach of serum fluorescence and conventional blood tests[J]. Oncotarget, 2016, 7(39): 64053-64070. DOI: 10.18632/oncotarget.11771.
[13]	MAN MR, ZHOU XL, LIU QH. Research progress of primary hepatocellular carcinoma biomarkers[J/CD]. E-J Transl Med, 2018, 5(11): 61-66. DOI: 10.12095/j.issn.2095-6894.2018.11.017. 满沐苒, 周旭林, 刘清华. 原发性肝癌肿瘤标志物研究进展[J/CD]. 转化医学电子杂志, 2018, 5(11): 61-66. DOI: 10.12095/j.issn.2095-6894.2018.11.017.
[14]	MANDEL P, METAIS P. Nuclear acids In human blood plasma[J]. C R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
[15]	LEON SA, SHAPIRO B, SKLAROFF DM, et al. Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res, 1977, 37(3): 646-650.
[16]	ONO A, FUJIMOTO A, YAMAMOTO Y, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy[J]. Cell Mol Gastroenterol Hepatol, 2015, 1(5): 516-534. DOI: 10.1016/j.jcmgh.2015.06.009.
[17]	PENG B, ZENG YL, LI ZY, et al. Technical progress of liquid biopsy in the diagnosis of liver cancer[J]. Chin J Exp Surg, 2020, 37(3): 578-582. DOI: 10.3760/cma.j.issn.1001-9030.2020.03.056. 彭渤, 曾永联, 李泽远, 等. 液体活检在肝癌诊断方面的技术进展[J]. 中华实验外科杂志, 2020, 37(3): 578-582. DOI: 10.3760/cma.j.issn.1001-9030.2020.03.056.
[18]	LIAO W, MAO Y, GE P, et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: A meta-analysis[J]. Medicine (Baltimore), 2015, 94(14): e722. DOI: 10.1097/MD.0000000000000722.
[19]	YAN L, CHEN Y, ZHOU J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma[J]. Int J Infect Dis, 2018, 67: 92-97. DOI: 10.1016/j.ijid.2017.12.002.
[20]	HUANG A, ZHANG X, ZHOU SL, et al. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma[J]. J Cancer, 2016, 7(13): 1798-1803. DOI: 10.7150/jca.15618.
[21]	TAO K, BIAN Z, ZHANG Q, et al. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma[J]. EBioMedicine, 2020, 56: 102811. DOI: 10.1016/j.ebiom.2020.102811.
[22]	LIAO W, YANG H, XU H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7(26): 40481-40490. DOI: 10.18632/oncotarget.9629.
[23]	AN Y, GUAN Y, XU Y, et al. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma[J]. Am J Transl Res, 2019, 11(10): 6462-6474.
[24]	QU C, WANG Y, WANG P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116.
[25]	XIONG Y, XIE CR, ZHANG S, et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma[J]. Cancer Manag Res, 2019, 11: 5745-5756. DOI: 10.2147/CMAR.S197455.
[26]	CAI J, CHEN L, ZHANG Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12): 2195-2205. DOI: 10.1136/gutjnl-2019-318882.
[27]	CAI Z, ZHANG J, HE Y, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma[J]. ESMO Open, 2021, 6(1): 100021. DOI: 10.1016/j.esmoop.2020.100021.
[28]	LIZUKA N, OKA M, SAKAIDA I, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers[J]. Clin Chim Acta, 2011, 412(1-2): 152-158. DOI: 10.1016/j.cca.2010.09.028.
[29]	SUN FK, FAN YC, ZHAO J, et al. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients[J]. Dig Dis Sci, 2013, 58(4): 1010-1015. DOI: 10.1007/s10620-012-2462-3.
[30]	LI F, FAN YC, GAO S, et al. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma[J]. Genes Chromosomes Cancer, 2014, 53(1): 90-97. DOI: 10.1002/gcc.22120.
[31]	KUO CC, LIN CY, SHIH YL, et al. Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas[J]. Clin Chem Lab Med, 2014, 52(8): 1235-1245. DOI: 10.1515/cclm-2013-0780.
[32]	JI XF, FAN YC, GAO S, et al. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(16): 4723-4729. DOI: 10.3748/wjg.v20.i16.4723.
[33]	HAN LY, FAN YC, MU NN, et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma[J]. Int J Med Sci, 2014, 11(2): 164-171. DOI: 10.7150/ijms.6745.
[34]	HUANG G, KROCKER JD, KIRK JL, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma[J]. Clin Chem Lab Med, 2014, 52(6): 899-909. DOI: 10.1515/cclm-2013-0885.
[35]	WEN L, LI J, GUO H, et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients[J]. Cell Res, 2015, 25(11): 1250-1264. DOI: 10.1038/cr.2015.126.
[36]	DOU CY, FAN YC, CAO CJ, et al. Sera DNA methylation of CDH1, DNMT3b and ESR1 promoters as biomarker for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma[J]. Dig Dis Sci, 2016, 61(4): 1130-1138. DOI: 10.1007/s10620-015-3975-3.
[37]	LU CY, CHEN SY, PENG HL, et al. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(4): 6406-6418. DOI: 10.18632/oncotarget.14115.
[38]	DONG X, HOU Q, CHEN Y, et al. Diagnostic value of the methylation of multiple gene promoters in serum in hepatitis B virus-related hepatocellular carcinoma[J]. Dis Markers, 2017, 2017: 2929381. DOI: 10.1155/2017/2929381.
[39]	HU N, FAN XP, FAN YC, et al. Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis B virus-associated hepatocellular carcinoma[J]. Tohoku J Exp Med, 2017, 242(2): 93-100. DOI: 10.1620/tjem.242.93.
[40]	KISIEL JB, DUKEK BA, V S R KANIPAKAM R, et al. Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, phase I pilot, and phase Ⅱ clinical validation[J]. Hepatology, 2019, 69(3): 1180-1192. DOI: 10.1002/hep.30244.
[41]	CHALASANI NP, RAMASUBRAMANIAN TS, BHATTACHARYA A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2021, 19(12): 2597-2605. e4. DOI: 10.1016/j.cgh.2020.08.065.
[42]	ELSEWIFY W, HASSAN EA, MEKKY MA, et al. Usefulness of circulating methylated p16 as a noninvasive molecular biomarker for hepatitis C-related hepatocellular carcinoma with normal serum alpha-fetoprotein levels[J]. Int J Gen Med, 2020, 13: 147-155. DOI: 10.2147/IJGM.S249272.
[43]	COHEN JD, LI L, WANG Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378): 926-930. DOI: 10.1126/science.aar3247.
[44]	GUO S, DIEP D, PLONGTHONGKUM N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nat Genet, 2017, 49(4): 635-642. DOI: 10.1038/ng.3805.
[45]	COHEN JD, JAVED AA, THOBURN C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proc Natl Acad Sci U S A, 2017, 114(38): 10202-10207. DOI: 10.1073/pnas.1704961114.
[46]	WAN L, GUO L, HU Y, et al. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer[J]. Clin Biochem, 2021, 89: 44-50. DOI: 10.1016/j.clinbiochem.2020.12.005.